Serious adverse events such as death, amputation, bone fracture, DKA, serious renal adverse events, complicated genitourinary tract infection, thromboembolic events, acute pancreatitis, and renal cell or bladder cancer, as an aggregate, were found to be decreased in our study in SGLT2-Is arm as compared to placebo. The gene discussed is SLC5A2; the disease is urinary bladder cancer.